Biogen (BIIB) option implied volatility flat into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
RBC Capital on Biogen (BIIB): 'CMS Makes It Clear - Leqembi Will Be Broadly Reimbursed - Should Reduce Overhang'
April 26, 2023 3:16 PM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $340.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "We believe many people have been on the sidelines on BIIB because of concerns around Leqembi events this year - upcoming competitor data from LLY, an AdComm, the PDUFA for potential full approval, and CMS decision on reimbursement. Our sense has been that reimbursement is the biggest uncertainty weighing on the stock and on perceptions around Leqembi's long-term potential, as despite CMS's contention they will broaden reimbursement as soon as the drug... More
